元姜汤同情用药治疗症状性心动过缓的研究解读
这项在中国北京开展的同情用药研究纳入184例症状性心动过缓患者,给予元姜汤200毫升每日两次共16周。16周时获得良好治疗结局的比例为60.87%,未报告严重不良事件;完成至少8周治疗与良好结局相关,而房室传导阻滞、当前吸烟及治疗前1个月内晕厥与不良结局相关。
要点
- 元姜汤同情用药16周良好结局比例60.87%,未报告严重不良事件。
- 完成至少8周治疗与16周良好结局显著相关(OR 2.053)。
- 房室传导阻滞、当前吸烟、治疗前1月内晕厥与不良结局相关。
核心结论
- 元姜汤同情用药治疗症状性心动过缓显示鼓舞性结局,未报告严重不良事件。
- 完成至少8周治疗与16周良好结局显著相关,房室传导阻滞、当前吸烟及治疗前1个月内晕厥与不良结局显著相关。
研究设计与样本
- 本研究为在中国北京开展的同情用药研究,时间范围为2019年1月至2020年1月。
- 共纳入184例症状性心动过缓患者,给予元姜汤(含6味中药)200毫升每日两次,治疗16周。
- 分析采用意向性治疗(ITT)方法,主要结局指标为16周时获得良好治疗结局的参与者比例。
主要发现
- 16周治疗期间,12例失联、21例终止研究,脱落率为17.93%。
- 最常见的治疗相关不良事件为口干(6.52%)、便秘(6.45%)和嗜睡(3.26%)。
- 良好治疗结局比例在4周时为65.22%,8周时为59.78%(OR 1.11,95%CI 0.71-1.73),12周时为61.41%(OR 1.16,95%CI 0.92-1.45),16周时为60.87%(OR 1.15,95%CI 0.98-1.35)。
- 多因素回归分析显示,16周良好结局与完成至少8周治疗显著相关(OR 2.053,95%CI 1.064-3.560)。
- 不良结局与房室传导阻滞(OR 0.255,95%CI 0.083-0.784)、当前吸烟(OR 0.343,95%CI 0.027-0.487)及治疗前1个月内晕厥(OR 0.321,95%CI 0.114-0.904)显著相关。
临床怎么用
- 对症状性心动过缓患者,元姜汤同情用药16周内未报告严重不良事件,但需关注口干、便秘和嗜睡。
- 治疗前应评估房室传导阻滞、吸烟状态及近期晕厥史,这些因素与不良结局相关。
- 完成至少8周治疗与更好结局相关,临床应关注治疗依从性。
局限性
- 本研究为同情用药研究,非随机对照设计,结果需谨慎解读。
- 脱落率为17.93%,可能影响结果稳定性。
- 研究样本来自单一地区,外推性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: No effective medication is available for symptomatic bradyarrhythmia, particularly in low socioeconomic status (SES) population. Objective: To explore the safety and efficacy of Yuanjiang decoction, a traditional Chinese medicinal prescription, for symptomatic bradyarrhythmia on a compassionate-use basis. Methods: This compassionate-use study was conducted in Beijing, China between January 2019 and January 2020. Eligible participants were recruited and treated with Yuanjiang decoction (composed of 6 Chinese herbal medicines), 200 ml twice daily for 16 weeks. Analyses were done with the intention-to-treat (ITT) approach. The primary outcome measure was the proportion of participants who achieved a favorable treatment outcome at 16 weeks. Results: As of January 2020, 184 patients were included. After 16-weeks treatment, 12 participants were lost to contact while 21 participants were terminated from this study, with a drop-out rate of 17.93%. The most common treatment-related adverse events were xerostomia (6.52%), constipation (6.45%) and sleepiness (3.26%). The proportion of participants with favorable treatment outcome was 65.22% at 4 weeks, 59.78% at 8 weeks (OR: 1.11, 95% CI: 0.71-1.73), 61.41% at 12 weeks (OR: 1.16, 95% CI: 0.92-1.45) and 60.87% at 16 weeks (OR: 1.15, 95% CI: 0.98-1.35). In the multifactor regression analysis, the favorable treatment outcome at 16 weeks was significantly associated with completing at least 8 weeks treatment (OR: 2.053, 95% CI: 1.064-3.560), while unfavorable treatment outcome was significantly associated with an atrioventricular block (OR: 0.255, 95% CI: 0.083-0.784), current smoking (OR: 0.343, 95% CI: 0.027-0.487), and syncope in the month before treatment (OR: 0.321, 95%CI: 0.114-0.904). Conclusion: This compassionate-use study showed encouraging outcomes of treatment with Yuanjiang decoction, without serious adverse events. This study identified several key factors that may affect outcomes. These findings helped inform the design and assess the feasibility of a large-scale randomized clinical trial.
引用
- Wan-Tong Z, Bao-Chen Z, Zhao L, et al. Compassionate Use of Yuanjiang Decoction, a Traditional Chinese Medicinal Prescription, for Symptomatic Bradyarrhythmia. Front Pharmacol. 2022. PMID: 35479315. doi:10.3389/fphar.2022.764930
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。